Remicade Infusion Management Program

Janssen Inc.1,630 enrolled

Overview

Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.

Study Type

OBSERVATIONAL

Enrollment

1,630

Conditions

Crohn Disease Arthritis, Rheumatoid

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is a good candidate to receive infliximab as per the Product Monograph * Subject is prescribed infliximab by an appropriate physician * Subject receives infusion in a community infusion centre. * Subject has signed the approved consent form. Exclusion Criteria: * Not specified in the protocol

Locations (2)

Unnamed facility

Montreal, Quebec, Canada

Unnamed facility

Pointe-Claire, Canada

Outcomes

Primary Outcomes

Type and frequency of infusion reactions

Time frame: Up to 7 years

Pre-infusion treatments and efficacy

Time frame: Up to 7 years

Infusion reaction management approaches

Time frame: Up to 7 years

The number of subjects with adverse events

Time frame: Up to 7 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.